3-hydroxy-3-methylglutaryl-coenzyme a has been researched along with Atherogenesis in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (90.91) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, X; Song, L; Xiang, D; Xie, D; Zhao, W | 1 |
| Banach, M; Jones, SR; Kapoor, K; Martin, SS; Sathiyakumar, V; Toth, PP | 1 |
| Pencina, M; Sniderman, AD; Thanassoulis, G | 1 |
| Baumgarten, G; Frede, S; Hilbert, T; Hoeft, A; Klaschik, S; Knuefermann, P; Poth, J | 1 |
| Ahmad, S; Bagga, P; Iqbal, D; Khan, A; Khan, MS; Srivastava, AK | 1 |
| Ashok, P; Poulose, DN; Singh, D; Suresh, B | 1 |
| Chen, GP; Du, CQ; Han, J; Li, L; Wu, T; Zhang, XQ | 1 |
| Chen, XY; Gou, SH; He, M; Huang, HF; Liu, J; Ma, YY; Ni, JM; Zhang, Y; Zhao, XN | 1 |
| Angelovich, TA; Hearps, AC; Jaworowski, A; Maisa, A; Shi, MD; Zhou, J | 1 |
| Chen, Y; Ku, Y; Ma, KL; Moorhead, JF; Powis, SH; Ruan, XZ; Varghese, Z | 1 |
| Dhale, MA; Gaonkar, V; Keni, S; Puttananjaiah, MK | 1 |
1 review(s) available for 3-hydroxy-3-methylglutaryl-coenzyme a and Atherogenesis
| Article | Year |
|---|---|
Novel Therapeutic Targets for Managing Dyslipidemia.
Topics: Acyl Coenzyme A; Angiopoietin-like Proteins; Animals; Apolipoproteins C; Atherosclerosis; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Molecular Targeted Therapy; Prospective Studies | 2018 |
10 other study(ies) available for 3-hydroxy-3-methylglutaryl-coenzyme a and Atherogenesis
| Article | Year |
|---|---|
Salvianolic acid A alleviates atherosclerosis by inhibiting inflammation through Trc8-mediated 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cytokines; Endothelial Cells; Humans; Inflammation; Mice; Mice, Knockout | 2023 |
ApoB.
Topics: Acyl Coenzyme A; Apolipoprotein B-100; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Chylomicrons; Evidence-Based Medicine; Humans; Lipoproteins, VLDL; Molecular Mimicry; Predictive Value of Tests; Risk Assessment; Risk Factors; Triglycerides | 2019 |
Anti-atherogenic effects of statins: Impact on angiopoietin-2 release from endothelial cells.
Topics: Acyl Coenzyme A; Angiopoietin-2; Atherosclerosis; Cell Survival; Cells, Cultured; Endothelial Cells; Exocytosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Nitric Oxide; Nitric Oxide Synthase Type III; Pravastatin; Simvastatin; Weibel-Palade Bodies | 2013 |
In vitro screening for β-hydroxy-β-methylglutaryl-CoA reductase inhibitory and antioxidant activity of sequentially extracted fractions of Ficus palmata Forsk.
Topics: Acyl Coenzyme A; Antioxidants; Atherosclerosis; Ficus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; In Vitro Techniques; Lipid Peroxidation; Oxidation-Reduction; Oxidative Stress; Plant Extracts; Plant Leaves | 2014 |
Evaluation of antihyperlipidemic potency of a polyherbomineral formulation (AF-LIP) in experimental animal models.
Topics: Acyl Coenzyme A; Animals; Atherosclerosis; Cholesterol; Diet, High-Fat; Dose-Response Relationship, Drug; Feces; Female; Fenofibrate; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Plant Extracts; Polyethylene Glycols; Rats; Rats, Wistar; Simvastatin | 2014 |
Alteration of mevalonate pathway in proliferated vascular smooth muscle from diabetic mice: possible role in high-glucose-induced atherogenic process.
Topics: Acyl Coenzyme A; Alkyl and Aryl Transferases; Animals; Aorta; Atherosclerosis; Blood Glucose; Cell Proliferation; Diabetes Mellitus, Experimental; Farnesyltranstransferase; Female; Geranylgeranyl-Diphosphate Geranylgeranyltransferase; Geranyltranstransferase; Glucose; Inflammation; Lipids; Mevalonic Acid; Mice; Mice, Inbred BALB C; Muscle, Smooth, Vascular | 2015 |
Lipid-lowering, hepatoprotective, and atheroprotective effects of the mixture Hong-Qu and gypenosides in hyperlipidemia with NAFLD rats.
Topics: Acyl Coenzyme A; Animals; Atherosclerosis; Biological Products; Diet, High-Fat; Gynostemma; Hypolipidemic Agents; Lipids; Liver; Male; Plant Extracts; Protective Agents; Rats; Rats, Sprague-Dawley | 2016 |
Ex vivo foam cell formation is enhanced in monocytes from older individuals by both extrinsic and intrinsic mechanisms.
Topics: Acyl Coenzyme A; Adult; Aged; Aged, 80 and over; Aging; Atherosclerosis; ATP Binding Cassette Transporter 1; Australia; Biological Transport; Cholesterol; Cross-Sectional Studies; Foam Cells; Gene Expression Regulation; Humans; Inflammation; Macrophages; Male; Middle Aged; Monocytes; Transendothelial and Transepithelial Migration; Young Adult | 2016 |
Sirolimus inhibits endogenous cholesterol synthesis induced by inflammatory stress in human vascular smooth muscle cells.
Topics: Acyl Coenzyme A; Atherosclerosis; Cells, Cultured; Cholesterol; Coronary Vessels; Endoplasmic Reticulum; Golgi Apparatus; Humans; Immunosuppressive Agents; Inflammation; Interleukin-1beta; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Muscle, Smooth, Vascular; Sirolimus; Sterol Regulatory Element Binding Protein 2 | 2010 |
Statins: 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors demonstrate anti-atherosclerotic character due to their antioxidant capacity.
Topics: Acyl Coenzyme A; Antioxidants; Atherosclerosis; Cholesterol; Humans; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Oxidation-Reduction; Oxidative Stress | 2011 |